EIN Presswire is celebrating 30 years! Follow us on Substack for customer insights, interviews, and more!

EIN Presswire is celebrating 30 years! Follow us on Substack for customer insights, interviews, and more!

World Media Directory · RSS · Email Newsletters

There were 1,696 press releases posted in the last 24 hours and 428,150 in the last 365 days.

Biomed Industries, Inc. Press Releases

33 Press Releases

Published on October 6, 2025 - 10:00 GMT

Biomed Industries, Inc. to Present Promising NA-921 Phase 2/3 Results for Rett Syndrome Treatment at EAPS 2025

Biomed Industries, Inc. to Present Promising NA-921 Phase 2/3 Results for Rett Syndrome Treatment at EAPS Conference, October 18-20, 2025 in Lisbon, Portugal. SAN JOSE, CA, UNITED STATES, October 6, 2025 /⁨EINPresswire.com⁩/ -- - Biomed Industries, Inc. ( …

Distribution channels: Chemical Industry, Companies ...
Published on September 30, 2025 - 13:30 GMT

Biomed Industries, Inc. Unveils Phase 2 Success of NA-931: an Oral Quadruple Receptor Agonist for Obesity at EASD 2025

Biomed Industries, Inc. Unveils Phase 2 Success of NA-931: a First-in Class Oral Quadruple Receptor Agonist for the Treatment of Obesity at EASD 2025 in Vienna SAN JOSE, CA, UNITED STATES, September 30, 2025 /⁨EINPresswire.com⁩/ -- - Biomed Industries, …

Distribution channels: Chemical Industry, Companies ...
Published on September 8, 2025 - 10:00 GMT

Biomed Industries to Present Phase 2 Results on NA-931-An Oral Alternative to Injectables for Obesity- EASD 2025 Austria

Biomed Industries, Inc. to Present Phase 2 Results on NA-931-a First-in Class Alternative to Injectables for the Treatment of Obesity-EASD 2025- Vienna-Austria SAN JOSE, CA, UNITED STATES, September 8, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. …

Distribution channels: Chemical Industry, Companies ...
Published on September 2, 2025 - 10:00 GMT

Biomed Industries to Present Pivotal Studies at Paris MASH 2025 with Breakthrough in Obesity and Liver Disease Therapies

Company to present clinical trial protocols for NA 941 and cross indication data readouts for NA 931/NA 941 supporting development in obesity and MASH. SAN JOSE, CA, UNITED STATES, September 2, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc., a …

Distribution channels: Chemical Industry, Companies ...
Published on August 20, 2025 - 18:36 GMT

Biomed Industries, Inc. Advances First-of-Its-Kind Oral NA-931 and Semaglutide Combination Therapy for Treating Obesity

Biomed Industries, Inc. Advances First-of-Its-Kind Oral NA-931 (Bioglutide) and Injectable Semaglutide Combination Therapy for the Treatment of Obesity SAN JOSE, CA, UNITED STATES, August 20, 2025 /⁨EINPresswire.com⁩/ -- SAN JOSE, Calif., Aug. 20, 2025 — …

Distribution channels: Chemical Industry, Companies ...
Published on August 4, 2025 - 10:00 GMT

Biomed Industries Presents Four Breakthrough Studies on Alzheimer’s, Rett Syndrome, and Obesity Therapies at AAIC 2025

Biomed Industries, Inc. Presents Four Pivotal Studies at AAIC 2025 Highlighting Breakthrough Therapies for Alzheimer’s, Rett Syndrome, and Obesity SAN JOSE, CA, UNITED STATES, August 4, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc., a leading …

Distribution channels: Chemical Industry, Companies ...
Published on July 22, 2025 - 10:00 GMT

Biomed Industries to Present Four Studies at AAIC 2025 on Breakthrough Alzheimer’s, Rett Syndrome, and Obesity Therapies

Biomed Industries, Inc. to Present Four Pivotal Studies at AAIC 2025 on Breakthrough Alzheimer’s, Rett Syndrome, and Obesity Therapies SAN JOSE, CA, UNITED STATES, July 22, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc., a leading biopharmaceutical …

Distribution channels: Chemical Industry, Companies ...
Published on July 17, 2025 - 10:00 GMT

Biomed Industries Unveils Promising Phase 2 Results of NA-931, First Oral Quadruple Agonist for Obesity at ENDO 2025

Biomed Industries, Inc. Unveils Promising Phase 2 Results of NA-931, First Oral Quadruple Receptor Agonist for the Treatment of Obesity at ENDO 2025 SAN JOSE, CA, UNITED STATES, July 17, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. (Biomed) today …

Distribution channels: Chemical Industry, Companies ...
Published on June 23, 2025 - 10:00 GMT

Biomed Industries Presents Breakthrough Phase 2 Results of NA-931, an Oral Quadruple Agonist for Obesity , at ADA 2025

Biomed Industries, Inc. Presents Breakthrough Phase 2 Results of NA-931, a First-in-Class Oral Quadruple Agonist for the Treatment of Obesity , at ADA 2025 SAN JOSE, CA, UNITED STATES, June 23, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. ( …

Distribution channels: Chemical Industry, Companies ...
Published on June 17, 2025 - 10:00 GMT

Biomed Industries, Inc. to Present Phase 2 Results of Oral Obesity Drug NA-931 and Host Press Conference at ADA 2025

Biomed Industries, Inc. to Present Phase 2 Results of NA-931, a First-in-Class Oral Therapy for Obesity, and Host a Press Conference at the ADA 025 SAN JOSE, CA, UNITED STATES, June 17, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. (Biomed) today …

Distribution channels: Chemical Industry, Companies ...
Published on June 11, 2025 - 10:00 GMT

Biomed Industries, Inc. to Unveil Unified Acceleration Platform at ADA 2025, Linking Alzheimer’s, Obesity, and Diabetes

Biomed Industries, Inc. to Unveil Unified Acceleration Platform at American Diabetes Association (ADA) 2025, Linking Alzheimer’s, Obesity, and Diabetes SAN JOSE, CA, UNITED STATES, June 11, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. (“Biomed”) …

Distribution channels: Chemical Industry, Companies ...
Published on May 5, 2025 - 11:32 GMT

Biomed Industries, Inc. to Present Phase 2 Results on NA-931—An Oral Alternative to Injectables for Obesity—at ADA 2025

Biomed Industries, Inc. to Present Phase 2 Results on NA-931—An Oral Medicine Alternative to Injectables for Obesity—at ADA Conference 2025 in Chicago SAN JOSE, CA, UNITED STATES, May 5, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. (“Biomed”) …

Distribution channels: Chemical Industry, Companies ...
Published on March 31, 2025 - 10:00 GMT

Biomed Industries CEO to Chair NeuroSciences 2025 and Present Breakthrough Research on Alzheimer’s Disease and Obesity

Biomed Industries, Inc. CEO to Chair NeuroSciences 2025 and Present Groundbreaking Research on Alzheimer’s, Obesity, and Rett Syndrome SAN JOSE, CA, UNITED STATES, March 31, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. (Biomed) announced today …

Distribution channels: Chemical Industry, Companies ...
Published on March 4, 2025 - 11:00 GMT

Biomed Industries, Inc. Announces Phase 2/3 Results of NA-921, with Superior Efficacy and Safety for Rett Syndrome

Biomed Industries, Inc. Announces Phase 2/3 Results of NA-921, with Strong Efficacy and Superior Safety for Rett Syndrome Treatment SAN JOSE, CA, UNITED STATES, March 4, 2025 /⁨EINPresswire.com⁩/ -- -- Biomed Industries, Inc. (Biomed) today announced the …

Distribution channels: Chemical Industry, Companies ...
Published on February 3, 2025 - 22:21 GMT

Biomed Industries, Inc. Engages with Medicare to Advance Oral Bioglutide as an Affordable Metabolic Disorder Treatment

Biomed Industries, Inc. Engages with Medicare to Advance Oral Bioglutide (NA-931) as an Affordable Treatment for obesity and other metabolic disorders SAN JOSE, CA, UNITED STATES, February 3, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. (Biomed) …

Distribution channels: Chemical Industry, Companies ...
Published on January 16, 2025 - 11:00 GMT

Biomed Industries, Inc. Expands Patent Protection for Novel Combination Therapy Targeting Obesity

Biomed Industries, Inc. Expands Patent Protection for Novel Combination Therapy Targeting Obesity SAN JOSE, CA, UNITED STATES, January 16, 2025 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. (Biomed) announced today at the JP Morgan Healthcare Conference …

Distribution channels: Chemical Industry, Companies ...
Published on December 18, 2024 - 17:09 GMT

Biomed Industries, Inc. to Present Promising Data on NA-931, a Quadruple Receptor Agonist for Obesity and Hypertension

Biomed Industries, Inc. to Present Promising Data on NA-931, a Quadruple Receptor Agonist for Obesity and Hypertension at the ICHH 2025 in Tokyo SAN JOSE, CA, UNITED STATES, December 18, 2024 /⁨EINPresswire.com⁩/ -- San Jose, CA — December 18, 2024 — …

Distribution channels: Chemical Industry, Companies ...
Published on December 10, 2024 - 11:00 GMT

Biomed Industries, Inc. to Present Combination Therapy Phase 2 Protocol of NA-931 and Tirzepatide at ICOCD-2025

Biomed Industries, Inc. will present combination therapy phase 2 clinical protocol of NA-931 and Tirzepatide at ICOCD on January 2–3, 2025, in Seattle, WA SAN JOSE, CA, UNITED STATES, December 10, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. ( …

Distribution channels: Chemical Industry, Companies ...
Published on November 25, 2024 - 21:13 GMT

Biomed Industries, Inc. Unveils Groundbreaking research on NA-931 as a Potential Treatment for Alcohol Use Disorder

Biomed Industries, Inc. Unveils Groundbreaking Research on NA-931 as a Potential Treatment for Alcohol Use Disorder at World Conference on Addiction Medicine SAN JOSE, CA, UNITED STATES, November 25, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. ( …

Distribution channels: Chemical Industry, Companies ...
Published on November 4, 2024 - 11:00 GMT

Biomed Industries Presented Phase I Results of its Oral Quadruple Receptor Agonist NA-931 at World Obesity Congress 2024

Biomed Industries, Inc. presented Phase 1 results of NA-931, an Oral Novel Quadruple Receptor Agonist for Weight Loss at the World Obesity Congress 2024 SAN JOSE, CA, UNITED STATES, November 4, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc., a …

Distribution channels: Chemical Industry, Companies ...

1 2 Next